Verdiva Bio initiates Phase I study of obesity drug
Verdiva Bio has dosed the first patient in a Phase I SAD study evaluating VRB-103, a once-weekly selective oral amylin analog, as a treatment for overweight and obesity.
The Phase I randomised, double-blind, placebo-controlled study will assess the safety and tolerability of VRB-103, in healthy patients with an elevated BMI.
The study will evaluate VRB-103 alone and in combination with VRB-101, including assessment of multiple combination dose ratios. Verdiva currently anticipates initial Phase I data at the end of 2026.
VRB-103 is the first known once-weekly, amylin receptor-selective, oral amylin peptide analog currently in clinical development. Preclinical data demonstrated VRB-103 to have a differentiated profile with strong potency and high amylin receptor selectivity, with a comparable pharmacokinetic profile to VRB-101.
“The initiation of the VRB-103 Phase I study marks an important milestone for Verdiva and highlights our growing momentum as we move our second oral peptide into the clinic,” said Steve Marso, Chief Medical Officer at Verdiva Bio. “Obesity is a complex, chronic disease, and we’re committed to developing differentiated next-generation obesity candidates. VRB-103 has the potential to deliver a convenient, once-weekly oral treatment, with a clinically meaningful efficacy and tolerability profile for patients looking for alternatives to GLP-1 therapies.”
VRB-103 is being developed to address both the induction and maintenance phases of weight loss in patients living with overweight or obesity.
Amylin agonism represents a non-incretin mechanism of action, offering an alternative therapeutic approach for patients with obesity/overweight, potentially including those who do not respond to or cannot tolerate GLP-1 therapies.
VRB-103 is designed to be amylin receptor-selective at human amylin receptor-1 and -3 relative to the human calcitonin receptor. It is in development as a monotherapy and in combination with VRB-101, a once-weekly oral GLP-1 analog.
